Recurrent/refractory neuroblastoma in children
Conditions
Interventions
experimental group:Irinotecan combined with temozolomide
healthy control group:Nil
Sponsors
Xinhua Hospital affiliated to Shanghai Jiao Tong University School Of Medicine
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: (1) 1 year old < age <= 18 years old; (2) Biopsy histopathological and immunohistochemical detection of neuroblastoma with reference to the diagnostic criteria for neuroblastoma recommended by COG, pathological classification (INPC) and international Neuroblastoma staging (INSS); (3) Recurrent NB means new lesions appearing in the primary or other places 4 weeks after CR arrival through multidisciplinary comprehensive treatment, and refractory NB is defined as the evaluation of curative effect through 2 to 4 courses of chemotherapy and progression disease (PD); (4) ECOG scale (ECOG-PS) <= 2; (5) Expected survival for at least 3 months; (6) Agree to the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) No antibiotics or gastrointestinal surgery was performed within 3 months. Use (e.g., sulfamethoxazole/trimethoprim) is permitted to prevent pneumocystis carinii pneumonia. (2) Patients with autoimmune diseases. (3) Patients with immunodeficiency. (4) Patients with recurrent/refractory diseases who have been treated. (5) Multiple organ failure. (6) Uncontrolled infection and diarrhea. (7) Drug allergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intestinal microbiota ;Chemotherapy response: complete response,very good partial response,partial response,mixed response,no response,stable disease and progressive disease.; | — |
Countries
China
Contacts
Public ContactZhang Xin
Xinhua Hospital affiliated to Shanghai Jiao Tong University School Of Medicine
Outcome results
None listed